EAN 2017

2:16
Studying patients at risk of dementia and defining subjective cognitive decline
Ondrej Lerch
4:26
Markers for the preclinical and prodromal stages of Parkinson’s disease
Wolfgang H. Oertel
1:06
Cerebrospinal fluid (CSF) and imaging biomarkers for the differential diagnosis of dementia
Philip Scheltens
4:31
Challenges of managing the neuropsychiatric symptoms of Alzheimer’s and vascular dementia
Pasquale Calabrese
3:31
ALS and frontotemporal dementia: on a continuum or part of a spectrum of disorders?
Manuela Neumann
3:07
ASL MRI as an early biomarker for Alzheimer’s disease
M. Hale Alpsan Gökmen
2:03
Strategies for the prevention of vascular cognitive impairment
Leonardo Pantoni
1:54
Challenges associated with diagnosing parkinsonian disorders
Kailash P. Bhatia
1:02
Investigating physical activity and Alzheimer’s disease
Kristian Steen Frederiksen
4:10
Atypical parkinsonian disorders
Kailash P. Bhatia
1:47
APOE haplotypes, ACE insertion/deletion polymorphism and neuropsychiatric symptoms in Alzheimer’s
Fabricio Ferreira De Oliveira
1:26
Cognitive performance stays stable in chronic kidney disease patients over a 2-year period
Janine Gronewold
2:41
Angiotensin receptor blockers on cognitive function in Alzheimer’s disease
Fabricio Ferreira De Oliveira
0:49
Outcome measures and comorbidities in dementia
Dorota Religa
1:17
Pioglitazone for the treatment of Alzheimer’s disease
Daniela Galimberti
1:24
Challenges with comorbidities and dementia
Dorota Religa
The content of VJDementia is intended for healthcare professionals